Home » Topics » BioWorld Science

BioWorld Science
RSS

Vaxart reports phase Ib data on oral bivalent norovirus vaccine

Sep. 26, 2019

Beijing Scitech-Mq Pharmaceuticals divulges EGFR and HER2 inhibitors

Sep. 26, 2019

Tyme Technologies begins pivotal stage of TYME-88-Panc trial with SM-88

Sep. 26, 2019

Celgene International II Sarl synthesizes new PDE4 inhibitors

Sep. 26, 2019

AzurRx reports phase II results for MS-1819 for exocrine pancreatic insufficiency in cystic fibrosis

Sep. 26, 2019

Phase IIa study of EDP-305 in NASH meets primary endpoint

Sep. 26, 2019

PharmaResources discloses new HBV antivirals

Sep. 26, 2019

Inflazome divulges new NLRP3 inhibitors

Sep. 26, 2019

New designer cytokine IC7Fc shows promise for type 2 diabetes

Sep. 26, 2019

SARM1: a new therapeutic target for MS and other neurodegenerative disorders

Sep. 26, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...